TY - JOUR
T1 - Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model
AU - Krishnan-Natesan, Suganthini
AU - Manavathu, Elias K.
AU - Cutright, Jessica L.
AU - Chandrasekar, Pranatharthi H.
PY - 2010/7/1
Y1 - 2010/7/1
N2 - In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole. Antifungal efficacy was evaluated by reduction of fungal burden in the tissues of infected animals at periodic intervals during the first day of treatment. The fungal burden in tissues of drug-treated mice was reduced compared with controls in a time-dependent manner. At 24h after drug treatment, a >2log10 reduction of fungal burden in the kidney was obtained in the anidulafungin- and caspofungin-treated mice compared with a ca. 1.2log10 reduction in fluconazole-treated mice (P<0.003). There was no significant difference in the splenic fungal burden at 24h. Thus, echinocandins have excellent antifungal activity in the early phase of disseminated Candida albicans infection and may contribute to an improved outcome in critically ill immunocompromised/neutropenic patients.
AB - In this study, we investigated the in vivo efficacy of anidulafungin during the early phase of disseminated candidiasis in a neutropenic murine model and compared the results with those obtained for fluconazole. Antifungal efficacy was evaluated by reduction of fungal burden in the tissues of infected animals at periodic intervals during the first day of treatment. The fungal burden in tissues of drug-treated mice was reduced compared with controls in a time-dependent manner. At 24h after drug treatment, a >2log10 reduction of fungal burden in the kidney was obtained in the anidulafungin- and caspofungin-treated mice compared with a ca. 1.2log10 reduction in fluconazole-treated mice (P<0.003). There was no significant difference in the splenic fungal burden at 24h. Thus, echinocandins have excellent antifungal activity in the early phase of disseminated Candida albicans infection and may contribute to an improved outcome in critically ill immunocompromised/neutropenic patients.
KW - Anidulafungin
KW - Candida albicans
KW - Candidiasis
KW - Drug efficacy
KW - Echinocandins
KW - Murine model
KW - Rapid killing
UR - http://www.scopus.com/inward/record.url?scp=77953020219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953020219&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2010.02.020
DO - 10.1016/j.ijantimicag.2010.02.020
M3 - Article
C2 - 20400270
AN - SCOPUS:77953020219
VL - 36
SP - 33
EP - 36
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
SN - 0924-8579
IS - 1
ER -